4.4 Granulocytes

Collecting Granulocytes

Granulocyte concentrates are collected by apheresis (granulocytapheresis) from a single donor, almost always after pharmacologic mobilization to raise the donor's circulating neutrophil count well above baseline. Standard mobilization combines granulocyte colony-stimulating factor (G-CSF, e.g., filgrastim), given subcutaneously, with or without a corticosteroid (dexamethasone or prednisone); G-CSF alone or in combination reliably yields more granulocytes than corticosteroid alone, though some centers use corticosteroid-only mobilization to avoid G-CSF-related donor bone pain and rare splenic complications.

During the apheresis procedure, a sedimenting agent — hydroxyethyl starch (HES) — is added to the collection circuit. Granulocytes are only slightly denser than red cells and sediment poorly on their own; HES promotes red cell rouleaux formation and accelerated sedimentation, letting the instrument separate a granulocyte-rich layer more efficiently. A direct consequence of HES-assisted collection is a higher red cell content in the final product than in other apheresis components, which drives the compatibility-testing requirements described below.

Product Specifications

Unlike every other cellular blood component, granulocytes are stored without agitation and at room temperature rather than refrigerated — refrigeration impairs granulocyte function and viability rather than preserving it, the opposite of the rule for red cells and whole blood.

Compatibility Testing and Required Modifications

Because a granulocyte unit always contains a clinically meaningful volume of red cells, it must be ABO- and Rh-compatible with the recipient and fully crossmatch-compatible, exactly as if it were a red cell transfusion — this differs from platelet or plasma components, where ABO compatibility is preferred but not always mandatory.

Granulocytes must always be irradiated before transfusion, without exception, because the concentrate inevitably contains a substantial number of viable lymphocytes and — unlike red cells or platelets — cannot be leukocyte-reduced, since filtration to remove leukocytes would remove the therapeutic granulocytes along with them. Irradiation is therefore the only available TA-GVHD risk-reduction strategy for this component.

Because leukoreduction is not an option, CMV risk reduction for granulocytes must come from donor selection: a CMV-seronegative granulocyte donor is required for a CMV-seronegative, at-risk recipient. The SBB should recognize this as the one component category where using a leukoreduced unit is not an available substitute strategy.

Emergency release is standard practice for granulocytes: because donor mobilization, collection, and product release must happen rapidly to meet the recipient's urgent clinical need, infectious disease testing results are frequently not yet available (typically returning 24-48 hours after collection) at the time the unit is issued. Facilities manage this risk by preferentially using repeat, previously tested donors when possible and by following documented emergency-release protocols.

Clinical Indications and Use

Granulocyte transfusions are reserved for patients with severe neutropenia (absolute neutrophil count typically under 500/µL) who have a documented bacterial or fungal infection that is not responding to appropriate antimicrobial therapy, and for whom bone marrow recovery is anticipated within a clinically meaningful timeframe. Granulocyte transfusion is a bridging therapy, not a definitive treatment, because transfused granulocytes have a circulating half-life of only about 6-8 hours. Typical recipients include patients with chemotherapy-induced neutropenia, aplastic anemia, or early post-hematopoietic stem cell transplant status, particularly pediatric patients and patients with refractory invasive fungal infection.

Because of the short half-life, granulocytes are typically given daily, or in children sometimes every other day, until the infection resolves or the marrow recovers — a single dose provides only transient benefit. Clinical trial evidence for efficacy has been mixed, which is why granulocyte transfusion remains a supportive, adjunctive therapy used selectively rather than a routine intervention, and why the SBB should understand it as physiologically sound but clinically variable in outcome.

HLA-matched or HLA-selected granulocyte donors may be sought for heavily alloimmunized recipients who have demonstrated poor responses to random-donor granulocytes or platelets, applying the same HLA-matching logic used for refractory platelet support.

Donor Considerations and Frequency Limits

Granulocyte donors undergo the same infectious-disease eligibility screening as other apheresis donors, plus specific counseling about G-CSF and corticosteroid effects (transient bone pain, leukocytosis, rare splenic enlargement or, extremely rarely, splenic rupture with G-CSF). Because repeat granulocyte donation from the same mobilized donor is common when a single recipient needs several sequential daily doses, facilities track cumulative G-CSF exposure and enforce minimum inter-donation intervals to protect donor safety, distinct from the shorter intervals allowed for unmobilized plateletpheresis or plasmapheresis donors.

Putting the Component Together

Granulocytes are the clearest example in this chapter of a product whose collection method (HES-assisted apheresis), storage rule (room temperature, no agitation, 24-hour life), compatibility requirement (full crossmatch due to red cell content), and required modification (mandatory irradiation, with CMV risk managed only through donor selection) all derive logically from one fact: this is a cellular product that cannot tolerate refrigeration, cannot be filtered, and carries an unavoidable red cell and lymphocyte load along with its therapeutic neutrophils. The SBB should be able to explain each specification as a direct consequence of that starting fact rather than memorizing it as an isolated number.